Baghdadi Azarakhsh, Luu Harry T, Shaghaghi Mohammadreza, Ghadimi Maryam, Simsek Cem, Xu Ziyi, Hazhirkarzar Bita, Motaghi Mina, Hammami Muhammad, Clark Jeanne M, Gurakar Ahmet, Kamel Ihab R, Kim Amy K
Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
Department of Medicine, Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD.
Transplant Direct. 2022 Oct 18;8(11):e1365. doi: 10.1097/TXD.0000000000001365. eCollection 2022 Nov.
With the rising incidence of hepatocellular carcinoma (HCC), more patients are now eligible for liver transplantation. Consequently, HCC progression and dropout from the waiting list are also anticipated to rise. We developed a predictive model based on radiographic features and alpha-fetoprotein to identify high-risk patients.
This is a case-cohort retrospective study of 76 patients with HCC who were listed for liver transplantation with subsequent liver transplantation or delisting due to HCC progression. We analyzed imaging-based predictive variables including tumor margin (well- versus ill-defined), capsule bulging lesions, volumetric analysis and distance to portal vein, tumor numbers, and tumor diameter. Volumetric analysis of the index lesions was used to quantify index tumor total volume and volumetric enhancement, whereas logistic regression and receiver operating characteristic curve (ROC) analyses were used to predict the main outcome of disease progression.
In univariate analyses, the following baseline variables were significantly associated with disease progression: size and number of lesions, sum of lesion diameters, lesions bulging the capsule, and total and venous-enhancing (viable) tumor volumes. Based on multivariable analyses, a risk model including lesion numbers and diameter, capsule bulging, tumor margin (infiltrative versus well-defined), and alpha-fetoprotein was developed to predict HCC progression and dropout. The model has an area under the ROC of 82%, which was significantly higher than Milan criteria that has an area under the ROC of 67%.
Our model has a high predictive test for patient dropout due to HCC progression. This model can identify high-risk patients who may benefit from more aggressive HCC treatment early after diagnosis to prevent dropout due to such disease progression.
随着肝细胞癌(HCC)发病率的上升,现在有更多患者符合肝移植条件。因此,预计HCC进展和从等待名单中退出的情况也会增加。我们基于影像学特征和甲胎蛋白开发了一种预测模型,以识别高危患者。
这是一项对76例等待肝移植的HCC患者进行的病例队列回顾性研究,这些患者随后因HCC进展接受了肝移植或被从等待名单中除名。我们分析了基于影像学的预测变量,包括肿瘤边缘(清晰与不清晰)、包膜突出病变、体积分析以及与门静脉的距离、肿瘤数量和肿瘤直径。对索引病变进行体积分析以量化索引肿瘤总体积和体积增强,而逻辑回归和受试者操作特征曲线(ROC)分析用于预测疾病进展的主要结局。
在单变量分析中,以下基线变量与疾病进展显著相关:病变大小和数量、病变直径总和、包膜突出的病变以及肿瘤总体积和静脉增强(存活)体积。基于多变量分析,开发了一种风险模型,包括病变数量和直径、包膜突出、肿瘤边缘(浸润性与清晰)以及甲胎蛋白,以预测HCC进展和退出。该模型的ROC曲线下面积为82%,显著高于ROC曲线下面积为67%的米兰标准。
我们的模型对因HCC进展导致患者退出具有较高的预测效能。该模型可以识别出高危患者,这些患者可能在诊断后早期从更积极的HCC治疗中获益,以预防因这种疾病进展而退出。